The estimated Net Worth of Argenio David Z D is at least $1.46 Миллион dollars as of 24 May 2017. Argenio D owns over 2,674 units of Simulations Plus stock worth over $1,102,678 and over the last 20 years Argenio sold SLP stock worth over $362,105.
Sign up
Argenio D SLP stock SEC Form 4 insiders trading
Argenio has made over 8 trades of the Simulations Plus stock since 2011, according to the Form 4 filled with the SEC. Most recently Argenio sold 2,674 units of SLP stock worth $31,232 on 24 May 2017.
The largest trade Argenio's ever made was selling 21,326 units of Simulations Plus stock on 22 May 2017 worth over $247,168. On average, Argenio trades about 2,771 units every 78 days since 2004. As of 24 May 2017 Argenio still owns at least 33,608 units of Simulations Plus stock.
You can see the complete history of Argenio D stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Argenio D's mailing address?
Argenio's mailing address filed with the SEC is 1220 W AVENUE J, , LANCASTER, CA, 93534.
Insiders trading at Simulations Plus
Over the last 21 years, insiders at Simulations Plus have traded over $70,055,940 worth of Simulations Plus stock and bought 24,000 units worth $1,395,840 . The most active insiders traders include Walter Swoltosz Virginia E ..., Walter S Woltosz и Momoko A Beran. On average, Simulations Plus executives and independent directors trade stock every 37 days with the average trade being worth of $571,025. The most recent stock trade was executed by Jill Fiedler Kelly on 9 September 2024, trading 2,250 units of SLP stock currently worth $21,848.
What does Simulations Plus do?
simulations plus, inc. (nasdaq: slp) is the premier developer of modeling & simulation software and consulting services supporting drug discovery, development research and regulatory submissions. we partner with companies to provide a data-driven, ‘strategic modeling methodology’, starting in early discovery, continuing through preclinical/clinical development, and concluding with clinical trials/post approval. with our subsidiaries, cognigen corporation and dilisym services, we offer #1-ranked, easy-to-use software (gastroplus™, admet predictor™, kiwi™, dilisym®, nafldsym®, pkplus™, and more) to bridge data mining, compound library screening with qsar models, pbpk/tk modeling & simulation in animals and humans following administration around the body, and quantitative systems pharmacology approaches. simulations plus technology is licensed to and used by regulatory agencies worldwide. for over 20 years, simulations plus has partnered with our clients to reduce costs and accelerate res
What does Simulations Plus's logo look like?
Complete history of Argenio D stock trades at Simulations Plus
Simulations Plus executives and stock owners
Simulations Plus executives and other stock owners filed with the SEC include:
-
Shawn M. O'Connor,
Chief Exec. Officer -
Shawn O'Connor,
Chief Executive Officer -
William Frederick,
CFO & Sec. -
John DiBella,
President, Lancaster Division -
John Anthony DiBella M.S.,
Pres of Lancaster Division -
Thaddeus Grasela,
Senior Advisory Capacity -
John Kneisel,
Chief Financial Officer -
Jill Fiedler-Kelly M.S., MS,
Pres of Cognigen Division -
Dr. Brett A. Howell Ph.D.,
Pres of DILIsym Services, Inc -
Dr. Brett A. Howell,
Pres of DILIsym Services, Inc -
John Paglia,
Independent Director -
Daniel Weiner,
Independent Director -
David Ralph,
Independent Director -
Walter Woltosz,
Chairman of the Board -
Walter S. Woltosz M.A.S., M.S.,
Co-Founder & Chairman -
Lisa LaVange,
Independent Director -
Renee Bouche,
IR Contact Officer -
Jill Fiedler-Kelly,
President - Cognigen division -
Dr. Scott Q. Siler,
Chief Scientific Officer of DILIsym Services, Inc -
Lindsay Luke,
Exec. Director of HR -
Arlene Padron,
Corp. Director of Marketing -
Viera Lukacova Ph.D.,
Chief Scientific Officer -
Argenio David Z D,
Director -
Brett Howell,
Business Unit President -
Steven Chang,
President, Immunetrics -
William W Frederick,
CFO -
Walter Swoltosz Virginia E ...,
-
Walter S Woltosz,
Director -
Richard R Weiss,
Director -
Momoko A Beran,
Chief Financial Officer -
Harold Wayne Rosenberger,
Director -
Jeffrey A Dahlen,
VP, Research & Development -
Virginia E Woltosz,
Secretary/Treasurer -
Ronald F Creeley,
VP Marketing & Sales -
Daniel Szot,
Chief Revenue Officer -
Sharlene Evans,
Director